Cochrane · systematic review · CD004028
Valproate for schizophrenia
Wang, Y, Xia, J, Helfer, B, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 14.3%Very low 2 · 28.6%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
VALPROATE + ANTIPSYCHOTICS versus ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinically significant response: important change As defined by each of the studies VALPROATE + ANTIPSYCHOTICS vs ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone | RR 1.31 [1.16, 1.47] | 14 studies · 1049 participants | Low Downgraded: risk of bias |
Leaving the study early: Acceptability of treatment Leaving the study early for any reason VALPROATE + ANTIPSYCHOTICS vs ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone | RR 0.76 [0.47, 1.24] | 11 studies · 951 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Leaving the study early: Overall tolerability Leaving the study early due adverse events VALPROATE + ANTIPSYCHOTICS vs ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone | RR 1.33 [0.9, 1.97] | 6 studies · 974 participants | Low Downgraded: risk of bias, imprecision |
Clinical response: Aggression/agitation Mean Modified Overt Aggression Rating Scale. Scale from: 0‐16 VALPROATE + ANTIPSYCHOTICS vs ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone | no estimate extracted | 3 studies · 186 participants | Very low Downgraded: risk of bias, inconsistency |
Adverse events: Sedation Number of participants with sedation/somnolence/drowsiness VALPROATE + ANTIPSYCHOTICS vs ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone | RR 1.38 [1.07, 1.79] | 8 studies · 770 participants | Low Downgraded: risk of bias |
Adverse events: Weight gain Number of participants with weight gain VALPROATE + ANTIPSYCHOTICS vs ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone | RR 1.17 [0.76, 1.82] | 4 studies · 427 participants | Low Downgraded: risk of bias, imprecision |
Quality of life: Clinically important change in quality of life ‐ as defined by individual studies VALPROATE + ANTIPSYCHOTICS vs ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone | no estimate extracted | 0 participants | Ungraded |